Results 21 to 30 of about 3,967 (153)

Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections [PDF]

, 2021
Introduction Infections due to carbapenem-resistant Gram-negative bacteria (CR-GNB) are increasingly frequent events, which are associated with a high mortality rate.
Bassetti, Matteo, Cenderello, Giovanni, Falletta, Antonio, Giacobbe, Daniele R., Vena, Antonio   +4 more
core   +1 more source

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

International Journal of Infectious Diseases, 2021
Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI).
Helio S. Sader, Mariana Castanheira, Leonard R. Duncan, Rodrigo E. Mendes   +3 more
doaj   +1 more source

Management of KPC-Producing Klebsiella pneumoniae Infections [PDF]

, 2015
Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) has become one of the most important contemporary pathogens, especially in endemic ...
M. Bassetti, D.R. Giacobbe, H. Giamarellou, C. Viscoli, G.L. Daikos, G. Dimopoulos, F.G. De Rosa, E.J. Giamarellos-Bourboulis, G.M. Rossolini, E. Righi, I. Karaiskos, M. Tumbarello, D.P. Nicolau, P.L. Viale, G. Poulakou, Rossolini, Munoz-Price, Grundmann, Maltezou, Giacobbe, Banerjee, Girmenia, Patel, Bauer, Arena, Kostrzewa, Rotova, Gaibani, Hoyos-Mallecot, Salimnia, Vincent, Arena, Paul, Zusman, Dickstein, Tzouvelekis, Tumbarello, Tumbarello, Daikos, Gutiérrez-Gutiérrez, Del Bono, Pea, Tenover, Clinical and Laboratory Standards Institute (CLSI), Nation, Capone, Monaco, Giacobbe, Giamarellou, Spyropoulou, Meletis, Karaiskos, Karaiskos, Sorlí, Sandri, Nation, Gonzalez-Padilla, Machuca, Stankowicz, Poulakou, Bassetti, Montravers, Bassetti, Ramirez, Wiskirchen, Giamarellou, Pontikis, Parker, Albiero, Lepak, Docobo-Pérez, Grabein, Shields, Temkin, Shields, Shields, Perez, Bulik, Giamarellou, Souli, Oliva, Cprek, Poulakou, Lu, Karvouniaris, Kollef, Rello, Solé-Lleonart, Palmer, Kalil, Monogue, Berthoin, Pea, Lorente, Ho, Kim, Keel, Martínez, Patel, Zarkotou, Falcone, Nguyen, de Oliveira, Dimopoulos, Chastre, Capellier, Havey, Matthaiou, Tacconelli, De Rosa, Sypsa, Gagliotti, Lin, Giacobbe, Munoz-Price, Tofteland, Schwaber, Lerner, De Rosa, Abdallah, Tumbarello, Giannella, Giannella, Giacobbe, Salsano, Sbrana, Girmenia, De Rosa, Forcina, Viale, Zuckerman, Saidel-Odes, Lübbert, Tascini, Oren, Tascini, Machuca, Bassetti, Falagas, Sutcliffe, Connors, Zhang, Solomkin   +142 more
core   +2 more sources

Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against KPC-Producing K. pneumoniae Collected from Bacteremic Patients, 2018 to 2020 [PDF]

, 2022
The management of KPC-producing K. pneumoniae (KPC-Kp) in bloodstream infections (BSIs) represent a serious clinical challenge. In this study, the aim is to assess the incidence of resistance to novel β-lactams-β-lactamase inhibitor combinations (βL ...
Ambretti S, Bovo F, Gaibani P., Lazzarotto T, Lombardo D   +4 more
core   +1 more source

The 2018 Garrod Lecture: Preparing for the Black Swans of Resistance [PDF]

, 2018
The need for governments to encourage antibiotic development is widely agreed, with ‘Market Entry Rewards’ being suggested. Unless these are to be spread widely – which is unlikely given the $1 billion sums proposed– we should be wary, for this approach ...
Livermore, David
core   +1 more source

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas Aeruginosa [PDF]

, 2021
Background: We aimed to describe the clinical characteristics and outcomes of patients treated with meropenem-vaborbactam (MEV) for a variety of gram-negative infections (GNIs), primarily including carbapenem-resistant Enterobacterales (CRE).
Abbo, Lilian M, Allen, David, Alosaimy, Sara, Amaya, Lee, Athans, Vasilios, Carlson, Travis J, Claeys, Kimberly C, Davis, Susan L, DeRonde, Kailynn, Garey, Kevin W, Jo, Jinhee, Jorgensen, Sarah C.J., Kufel, Wesley D, Lagnf, Abdalhamid M, Miller, Mathew, Molina, Kyle C, Morrisette, Taylor, Mynatt, Ryan, Ortwine, Jessica, Rybak, Michael J, Saw, Stephen, Scipione, Marco R, Vega, Ana D, Venugopalan, Veena, Veve, Michael, Yost, Christine, Zhao, Jing J   +26 more
core   +4 more sources

Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018–2022) [PDF]

, 2023
Funding Information: Open access funding provided by Università degli Studi di Torino within the CRUI-CARE Agreement. This research was supported by EU funding within the MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project ...
Almeida, André, Bastos, Paulo, Bianco, Gabriele, Boattini, Matteo, Cavallo, Rossana, Comini, Sara, Corcione, Silvia, Costa, Cristina, De Rosa, Francesco Giuseppe   +8 more
core   +1 more source

The European Medicines Agency Approved the New Antibacterial Drugs – Response to the 2017 Who Report on the Global Problem of Multi-Drug Resistance

Postępy Mikrobiologii, 2021
The growing problem of antimicrobial resistance has been classified by the World Health Organization (WHO) as one of the top ten threats to mankind. In a special report published in 2017, the WHO presented a list of microorganisms for which the search ...
Krajewska Joanna, Laudy Agnieszka Ewa
doaj   +1 more source

A Post-Neurosurgical Infection due to KPC-Producing Klebsiella pneumoniae Treated with Meropenem-Vaborbactam: A Case Report

International Journal of Infectious Diseases, 2022
This case report describes a patient with post-neurosurgical infection and bacteremia caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae.
Seohyun Choi, Marianna Fedorenko, Janet Lin-Torre, Nirav Mistry, Steven Smoke   +4 more
doaj   +1 more source

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam

Infectious Diseases and Therapy, 2020
Plain Language Summary Carbapenem-resistant gram-negative pathogens, specifically, Enterobacteriaceae, remain an urgent public health threat, and safe, effective treatment options are limited. The antibiotic agents meropenem and vaborbactam were selected
Eric Wenzler, Patrick J. Scoble
doaj   +1 more source